Biggest News Aggregation in the World

Dr Michael Shi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dr Michael Shi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dr Michael Shi Today - Breaking & Trending Today

Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia - Vimarsana News

Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

Published: August 24, 2023

Sovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopenia in China.

Source: onclive.com

Related Topics:

Ren Chi Yang Michael Shi Institute Of Hematology National Medical Products Administration Of China Chinese Academy Of Medical Sciences Blood Diseases Hospital Chinese Academy Medical Sciences National Medical Products Administration Dr Michael Shi Primary Immune Thrombocytopenia Hematologic Oncology Phase 3 Eslim 01 Trial Nct05029635

$FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer - Vimarsana News$

FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer

Published: March 31, 2023

A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.

Source: onclive.com

Related Topics:

United States Hutchinson China Meditech North America Asia Pacific China Meditech Patients With Refractory Metastatic Colorectal Cancer Fresco 2 Trial Fruquintinib Plus Best Supportive Care Dr Michael Shi